4-AcO-DiPT Facts
Psychedelic;
Description
4-AcO-DiPT (4-acetoxy-N,N-diisopropyltryptamine) — Ipracetin, Aces — is a synthetic psychedelic of the tryptamine class. It activates serotonin receptors and serotonin transporters,[1][2] producing both psychedelic and empathogenic effects.
Subjective effects include visual distortion, mood elevation, empathogenic warmth, stimulation, and introspective depth. The experience is a compressed hybrid — intense psychedelic and empathogenic qualities packed into a few hours, more stimulating than 4-AcO-DMT and carrying an emotional warmth its close relatives lack.[3]
4-AcO-DiPT produces no physical dependence and carries low abuse liability.[4] The main danger is psychological — panic and distress that scale with dose — and combining it with MAOIs can trigger a potentially fatal serotonin overload; frequent use poses an unstudied cardiovascular risk.[1]
Dose and durationby route · individual sensitivity varies
Starts in 15 – 40 minLasts 3 – 4 hoursAfter-effects 2 – 6 hours
Body and dependence
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Physical dependence
- None
- Psychological dependence
- Low
- Withdrawal
- None recorded
- Compulsive redosing
- Low
Tolerance
- Builds
- Rapid
- Fully resets after
- 7 days
- Carries over to
- psilocybin;
psilocin; LSD; mescaline; 4-AcO-DMT; 4-HO-MET; 4-HO-MiPT
Effectslikely at a common dose
- Perception
- Touch enhancement;
Visual drifting; Music enhancement; Color enhancement; Geometry; Visual breathing; +30 possible, including Spatial disorientation, Vestibular distortion, Visual haze / noise - Body
- Spontaneous body sensations;
Pupil dilation; Body high; +30 possible, including Temperature dysregulation, Nausea, Insomnia - Thinking
- Novelty enhancement;
+34 possible, including Cognitive impairment, Decision impairment, Suggestibility enhancement - Feeling
- none likely · 8 possible, including Emotional lability, Anxiety
- Self
- none likely · 10 possible, including Derealization, Depersonalization
- Time
- Time alteration;
+2 possible, including Temporal disorientation - Transpersonal
- none likely · 1 possible
- Awareness
- none likely · 5 possible
Who shouldn't take it
Combinations61 recorded
Seek help immediately if
Most difficulty is psychological (intense fear, panic, confusion) and passes with calm support — the signs below mean seek emergency help:
- Very high body temperature; hot, dry skin
- Seizures
- Chest pain; fast or irregular heartbeat
- Severe muscle rigidity, tremor, or twitching (possible serotonin syndrome)
- Cold, pale, or blue fingers/toes — severe vasoconstriction (notably NBOMe / DOx)
- Persistent vomiting; unconsciousness; uncontrollable agitation or risk of self-harm
What to do
- Stay calm and reassure — remind them they took a drug and the effect will pass
- Move to a calm, quiet, safe space with low light; reduce noise and sensory input
- Keep them from harm — they may act on fear or confusion; stay with them, don't leave them alone
- Talk them down gently; don't grab or restrain unless they're in danger
- For the medical signs above (overheating, seizure, chest pain, vasoconstriction, unresponsive) call emergency services
- If overheating, cool the body; be ready to give rescue breaths / CPR
The experience is time-limited and usually resolves with calm reassurance in a safe setting — psychological first aid, not medication. Serious physical harm is uncommon for classic psychedelics (LSD, psilocybin) but real for some potent phenethylamines (NBOMe, DOx), where hyperthermia, seizures, and vasoconstriction warrant emergency care.
988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE
References
- [1]^abKelly TJ, Bonniwell EM, Mu L, Liu X, Hu Y, Friedman V, Yu H, Su W, McCorvy JD, Liu QS (2024) Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala — Neuropsychopharmacology doi:10.1038/s41386-023-01744-8
- [2]^Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens — European Neuropsychopharmacology doi:10.1016/j.euroneuro.2016.05.001
- [3]
- [4]^Tittarelli R, Mannocchi G, Pantano F, Romolo FS (2015) Recreational use, analysis and toxicity of tryptamines. — Current neuropharmacology doi:10.2174/1570159x13666141210222409